Drug
Somapacitan
Somapacitan: highest development phase Phase 3, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| Somapacitan NCT03811535 | Phase 3 | Growth Hormone Deficiency in Children |
Latest
No recent events.
Follow Somapacitan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.